CD163, Rat, mAb ED2
Monoclonal antibody ED2 reacts with rat CD163 cell surface glycoprotein, a 175 kDa molecule also known as ED2. CD163 is expressed by approximately 50% of peritoneal macrophages, a subset of splenic macrophages, and by macrophages in most other tissues. However, it is not expressed by monocytes, alveolar macrophages or microglial cells. Macrophage scavenger receptor CD163 also known as hemoglobin scavenger receptor (HbSR) is a member of the scavenger receptor cysteine-rich family (SRCR). Scavenger receptors have been studied primarily for their ability to bind and internalize modified lipoproteins. They have been found to be involved in the development of atherosclerosis. Scavenger receptors also function as pattern recognition receptors for a wide variety of pathogens indicating a potential role in host defence. CD163 is involved in the endocytosis of hemoglobin:haptoglobin complexes and is able to counter oxidative tissue damage induced by hemoglobin after hemolysis. Recent results identify new anti-inflammatory and cytoprotective effector pathways in monocytes/macrophages related to hemoglobin scavenging and metabolism, which may be relevant for atheroprotection and wound healing.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP ResearchBridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis